Hemophilia Treatment Center - Case Study
Gene therapy for hemophilia B has just received approval from both the EMA and FDA. A 20-year-old patient with severe hemophilia B comes to your HTC for a regular visit and expresses interest in getting treatment with gene therapy. How would you respond to the following questions regarding the decision making process, the administration of treatment, and post-treatment monitoring?
Faculty
Carmen Escuriola-Ettingshausen, MD
Director, Haemophilia Centre Rhein-Main
Frankfurt-Mörfelden, Germany
Bjorn Habermann, MD
Orthopedic Surgeon
Frankfurt, Germany
Director, Haemophilia Centre Rhein-Main
Frankfurt-Mörfelden, Germany
Bjorn Habermann, MD
Orthopedic Surgeon
Frankfurt, Germany
Wolfgang A. Miesbach, MD, PhD
Goethe University Hospital
Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre
Frankfurt/Main, Germany
Anita Pathil-Warth, MD
Hepatologist
University of Frankfurt
Frankfurt, Germany
Steffen Rauchfuss, MD
Center Coordinator
University Hospital Frankfurt
Frankfurt, Germany
Joachim Schwable, MD
Department of Apheresis and Cell Processing and Inpatient Blood Donation
Deutsches Rotes Kreuz-Blood Donation Service
Frankfurt, GermanyFrankfurt/Main, Germany
Center Coordinator
University Hospital Frankfurt
Frankfurt, Germany
Joachim Schwable, MD
Department of Apheresis and Cell Processing and Inpatient Blood Donation
Deutsches Rotes Kreuz-Blood Donation Service
Frankfurt, GermanyFrankfurt/Main, Germany
